Kyverna Therapeutics

United States - Emeryville, California

• 03/08/2023
• Series B
• $60,000,000

Kyverna is a cell therapy company engineering and developing a new class of curative living medicines for inflammatory and autoimmune diseases. Using its SmarTcell™ approach which includes synReg-T cell and synNotch CAR-T technology platforms, Kyverna reprograms T cells to target and selectively suppress or eliminate autoreactive immune cells. The company’s goal is to develop therapies that are selective, potent and durable to tame autoimmunity.

We build interdisciplinary teams that bring a broad range of experiences and scientific expertise together to develop medicines that will free patients from the siege of autoimmune diseases and bring curiosity for exploring and creating the unknown. Our commitment to our employees is to foster an open, supportive, and inclusive environment where we create opportunities for individuals to learn and grow to their full potential at every level.

synNotch is a trademark of Gilead/Kite.

Related People

Dominic BorieFounder

United States - San Francisco Bay Area

Pharmaceutical executive with 18+ years experience in drug development spanning target discovery and validation, first-in-human studies, dose-ranging and pivotal trials, and medical affairs activities. Experienced drug-developer, designing/overseeing clinical trials in various fields of inflammation such as but not limited to inflammatory bowel diseases, rheumatoid arthritis, psoriasis, and organ transplantation. Experienced in interacting with global (US &EU) health authorities, including filing of INDs, CTAs, and sBLAs. Experienced leader of cross-functional teams (e.g. Development, Commercialization, Regulatory, Safety, Manufacturing, Payer). Experienced in interacting with key opinion leaders (both US and EU) and in setting up and running advisory boards and investigator meetings. Physician-scientist (Immunologist) with extensive experience in life-science research; both in academic and industry environments. Experienced digestive tract and liver transplant surgeon with 15+ years experience in the French healthcare system and in the treatment and monitoring of liver transplant recipients and patients with gastro-intestinal diseases (IBD, cancer).

LinkedIn https://www.linkedin.com/in/dominic-borie-m-d-ph-d-17a32213/